Fol­low­ing 2019 re­jec­tion, FDA ad­comm votes against Lex­i­con's type 1 di­a­betes and CKD drug

For the sec­ond time in five years, an FDA ad­vi­so­ry com­mit­tee vot­ed against en­dors­ing the ben­e­fit-risk pro­file of Lex­i­con’s drug so­tagliflozin.

The En­docrino­log­ic and Meta­bol­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER